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IMPORTANCE After the occurrence of nonfatal cardiovascular events, recurrent events are
highly likely. Most cardiovascular outcomes trials analyze first events only; extending analyses
to first and recurrent (total) events can provide clinically meaningful information.
OBJECTIVE To investigate whether liraglutide is associated with reduced first and recurrent
total major adverse cardiovascular events (MACE) compared with placebo among patients
with type 2 diabetes and high risk of cardiovascular events.
DESIGN, SETTING, AND PARTICIPANTS This post hoc analysis of the Liraglutide Effect and
Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) randomized,
double-blind, clinical trial included data from patients with type 2 diabetes who had
established or were at high risk for cardiovascular disease at 410 sites in 32 countries from
August 2010, to December 2015. Data analysis was performed from August 15, 2016, to
July 5, 2019.
INTERVENTIONS Patients were randomized 1:1 to receive liraglutide (up to 1.8 mg per day)
or placebo, both with standard care, for 3.5 to 5.0 years.
MAIN OUTCOMES AND MEASURES Assessed outcomes were MACE (cardiovascular death,
nonfatal myocardial infarction, and nonfatal stroke), expanded MACE (primary MACE plus
coronary revascularization and hospitalization for heart failure or unstable angina pectoris),
and the individual end points.
RESULTS The 9340 LEADER trial participants (6003 [64.3%] male; mean [SD] age, 64.3 [7.2]
years) experienced 1605 total MACE (1302 first and 303 recurrent events; median follow-up,
3.8 years [range, 0-5.2 years]). Patients who experienced any MACE were older (1 MACE:
mean [SD] age, 65.6 [8.0] years; >1 MACE: 65.7 [7.9] years) and had diabetes for longer
duration (1 MACE: mean [SD] duration, 13.4 [8.3] years; >1 MACE: 14.4 [8.7] years) compared
with patients without MACE (mean [SD] age, 64.1 [7.1] years; mean [SD] duration, 12.7 [7.9]
years). Fewer first and recurrent MACE occurred in the liraglutide group (n = 4668; 608 first
and 127 recurrent events) than in the placebo group (n = 4672; 694 first and 176 recurrent
events). Liraglutide was associated with a 15.7% relative risk reduction in total MACE
(hazard ratio [HR], 0.84; 95% CI, 0.76-0.93) and a 13.4% reduction in total expanded MACE
(HR, 0.87; 95% CI, 0.81-0.93) compared with placebo. For most individual cardiovascular end
points, liraglutide was associated with lower risk vs placebo.
CONCLUSIONS AND RELEVANCE These results suggest that liraglutide treatment is associated
with reduced total MACE compared with placebo among patients with type 2 diabetes and
high risk of cardiovascular events. This analysis supports the findings of an absolute benefit
of liraglutide treatment with respect to the overall burden of cardiovascular events in this
high-risk patient population.
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S everal cardiovascular (CV) outcomes trials with antihy-perglycemic therapies have shown significant CV ben-efits for patients with type 2 diabetes at high risk of CV
events, including Empagliflozin Cardiovascular Outcome Event
Trial in Type 2 Diabetes Mellitus Patients—Removing Excess
Glucose, and Mortality in Type 2 Diabetes (EMPA-REG
OUTCOME),1 Liraglutide Effect and Action in Diabetes: Evalu-
ation of Cardiovascular Outcome Results (LEADER),2-4 Trial to
Evaluate Cardiovascular and Other Long-term Outcomes With
Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN 6),5
Canagliflozin Cardiovascular Assessment Study (CANVAS),6
and Harmony Outcomes.7
The LEADER trial was a randomized, double-blind, pla-
cebo-controlled CV outcomes trial of the glucagon-like pep-
tide 1 (GLP-1) analog liraglutide (maximum 1.8 mg per day) vs
placebo, both added to standard care, for 3.5 to 5.0 years among
patients with type 2 diabetes and high risk for CV disease that
was conducted at 410 sites in 32 countries from August 2010
to December 2015.2 The primary analysis showed superiority
of liraglutide compared with placebo for major adverse CV
events (MACE)—a composite end point of CV death, nonfatal
myocardial infarction (MI), or nonfatal stroke (hazard ratio
[HR], 0.87; 95% CI, 0.78-0.97; P = .01 for superiority).2
Most CV outcomes trials evaluating diabetes therapies used
time to first MACE as the primary end point.1,2,5,6 However, af-
ter an initial nonfatal event, there is a high likelihood of a re-
current CV event.8 A total events analysis capturing both first
and recurrent events may provide important information to
help guide clinical decision-making from the perspectives of
both patient risk and economics.
We evaluated the association between the liraglutide and
total (ie, first and recurrent) occurrences of any MACE and ex-
panded MACE (primary MACE plus coronary revasculariza-
tion and hospitalization for heart failure or unstable angina pec-
toris). We hypothesized that liraglutide would be associated
with reduced total MACE compared with placebo.
Methods
In this novel, post hoc analysis of the LEADER randomized
clinical trial, we used models generalized from Cox propor-
tional hazards regression models to estimate the association
of liraglutide with the risk of total MACE, total expanded MACE,
and the individual CV end points in the LEADER trial. The
LEADER methods have been reported previously.2,9 The trial
included patients at least 50 years old with type 2 diabetes and
either established CV disease or chronic kidney disease, or at
least 60 years old with 1 or more CV risk factors. Among the
exclusion criteria were type 1 diabetes; the use of GLP-1–
receptor agonists, dipeptidyl peptidase-4 inhibitors, pramlin-
tide, or rapid-acting insulin; a familial or personal history of
multiple endocrine neoplasia type 2 or medullary thyroid can-
cer; and the occurrence of an acute coronary or cerebrovas-
cular event within 14 days before screening and randomiza-
tion. The trial was conducted at 410 sites across 32 countries
between August 2010, and December 2015. The protocol was
approved by the relevant institutional review board or ethics
committee at each participating center. Each patient pro-
vided written informed consent before participating. Events
were adjudicated by an external events adjudication commit-
tee, who determined whether multiple events for 1 patient con-
stituted separate events or were all related to the same event.2,9
Statistical Analysis
Post hoc data analysis was performed from August 15, 2016,
to July 5, 2019. Baseline characteristics are presented as mean
values and SDs for continuous variables, and the number of
patients and proportion (%) for categorical variables. Rela-
tive risks of CV events in the liraglutide compared with pla-
cebo group are presented as HRs and 95% CIs. To analyze data,
SAS, version 9.4 Proc Phreg (SAS Institute Inc) was used, ap-
plying Andersen-Gill (AG) Proportional Intensity and Prentice-
Williams-Petersen (PWP) models.
AG Proportional Intensity Model for Recurrent Events
The AG model originates from the Cox proportional hazards
regression model and assumes that the baseline intensity is the
same across time independent of the number of events.10,11
Thus, there is no inherited assumption in the model that an
event will decrease or increase the likelihood of the next event.
Adjudicated separate events within patients were assumed to
be independent of each other, which is considered to be a strong
assumption. For the AG model, time-dependent variables could
be incorporated to mitigate the assumption of indepen-
dence; for example, this could be the number of previous
events (or functions thereof) for each patient at the time of
a recurrent event.10,11 We used 2 AG models: the unadjusted
AG model included randomized treatment only, whereas
the adjusted AG model included previous events as a time-
dependent continuous variable and randomized treatment as
a fixed factor. In both AG models, we used the robust (sand-
wich) estimator of the variance with patient as the cluster to
account for dependence between events within patients.12
PWP Survival Model for Recurrent Events
The PWP model is different from the AG model because the
baseline intensity is allowed to vary depending on the num-
ber of events, as the model is stratified on this group.10,11 Thus,
Key Points
Question Does the association of liraglutide with a lower risk of
major adverse cardiovascular events remain when first and
subsequent events are included?
Findings In this post hoc analysis of the Liraglutide Effect and
Action in Diabetes: Evaluation of Cardiovascular Outcome Results
(LEADER) randomized clinical trial, among 9340 participants with
type 2 diabetes and high risk of cardiovascular events, a total of
1605 major adverse cardiovascular events occurred, comprising
1302 first and 303 recurrent events. Liraglutide was associated
with a 15.7% relative risk reduction for total major adverse
cardiovascular events vs placebo.
Meaning These data support the efficacy of liraglutide among
patients with type 2 diabetes and high risk of cardiovascular
events.
Liraglutide and MACE in Patients With Diabetes and High Cardiovascular Risk Original Investigation Research
jamacardiology.com (Reprinted) JAMA Cardiology December 2019 Volume 4, Number 12 1215
© 2019 American Medical Association. All rights reserved.
the baseline hazard is allowed to be different within the num-
ber of events. All patients are at risk for a first event, but a pa-
tient could only be at risk for a recurrent event after the first
event has occurred. The PWP model can incorporate both com-
mon and event-specific effects for each covariate; therefore,
unlike the AG model, the effect of covariates may vary from
event to event in the PWP model (ie, the effect of randomized
treatment can differ according to event order).10,11 We used the
PWP–total-time model for results pertaining to the PWP model
with treatment as a fixed factor. The PWP–total-time model
used the same data structure as the AG model but with a
supplementary stratum variable defined by the number of
events within each patient. Other than the adjustments de-
tailed above, no other adjustments were made for baseline
characteristics in these analyses.
Mean Cumulative Function and Number Needed to Treat
The mean cumulative function was estimated using the Nelson-
Aalen nonparametric method. The number needed to treat
(NNT) for event prevention was based on the difference be-
tween the mean cumulative function for each treatment arm
at 3 years.13 A sensitivity analysis was performed to account
for non-CV death as competing risk, which was estimated with
the mean cumulative function, as per previously published
methods.14,15
Results
Baseline Characteristics and Distribution of MACE,
Expanded MACE, and Individual CV End Points
A total of 1605 MACE occurred among 9340 LEADER trial par-
ticipants (6003 [64.3%] male; mean [SD] age, 64.3 [7.2] years);
1302 were first events, and 303 were recurrent events (Figure 1).
On average, patients who experienced any MACE were older
(1 MACE: mean [SD] age, 65.6 [8.0] years; >1 MACE: 65.7 [7.9]
years) and had a longer duration of diabetes (1 MACE: mean
[SD] duration, 13.4 [8.3] years; >1 MACE: 14.4 [8.7] years) com-
pared with patients without MACE (mean [SD] age, 64.1 [7.1]
years; mean [SD] diabetes duration, 12.7 [7.9] years). Patients
who experienced any MACE had higher hemoglobin A1c lev-
els, and more frequent prior MI and/or heart failure at base-
line compared with those who did not experience a MACE
(Table). A history of MI at baseline was more common among
those who experienced recurrent MACE compared with the
none and single groups (Table). There was a median (range)
follow-up of 3.8 (0-5.2) years,2 allowing robust analyses of data
at 3 years.
Fewer first and recurrent MACE occurred in the liraglu-
tide group (n = 4668 randomized participants; 608 first events
and 127 recurrent events) compared with the placebo group
(n = 4672 randomized participants; 694 first events and 176
recurrent events) (Figure 1A). Overall, there were 135 fewer total
MACE with liraglutide compared with placebo (735 vs 870
events) (Figure 1A). This translated to an NNT of 43 patients
to prevent 1 event at 3 years (Figure 2) and an NNT of 37 pa-
tients when accounting for non-CV death as competing risk.
The mean cumulative functions taking into account non-CV
Figure 1. Total First and Recurrent Cardiovascular Events
During the LEADER Trial
Individual cardiovascular end pointsC
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Analysis included the total number of randomized patients in the liraglutide
group (n = 4668) and in the placebo group (n = 4672). Hazard ratios (HRs)
(95% CIs) for recurrent events were calculated using the pooled treatment
effects across event numbers of 2 or more from the Prentice-Williams-Peterson
model. A, The 3-point composite end point included time to cardiovascular
death, nonfatal myocardial infarction, or nonfatal stroke. First events: HR, 0.87
(95% CI, 0.78-0.97); recurrent events: HR, 0.85 (95% CI, 0.67-1.07). B, The
6-point composite end point included the 3-point major adverse cardiovascular
event end points plus coronary revascularization and hospitalization for heart
failure or unstable angina pectoris. First events: HR, 0.88 (95% CI, 0.81-0.96);
recurrent events: HR, 0.97 (95% CI, 0.87-1.07).
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death was lower in both treatment groups but more marked
in the liraglutide group (Figure 2). Recurrent MACE occurred
in 97 of 4668 patients (2.1%) receiving liraglutide and in 126
of 4672 (2.7%) receiving placebo; this finding was associated
with reductions in the proportions of patients experiencing re-
current nonfatal MI and stroke. Fewer patients experienced re-
current expanded MACE with liraglutide (416 of 4668 [8.9%])
compared with placebo (471 of 4672 [10.1%]), with correspond-
ingly fewer total events (Figure 1B). For expanded MACE, the
NNT was estimated to be 23 patients at 3 years (Figure 2), and
21 patients when non-CV death was included as a competing
risk. Overall, few patients experienced recurrent events of in-
dividual CV end points, and (with the exception of unstable
angina pectoris) consistently lower numbers of recurrent events
occurred with liraglutide compared with placebo (Figure 1C).
The most prevalent recurrent expanded MACE (n = 1669
events) were coronary revascularization (710 [42.5%]) and hos-
pitalization for heart failure (385 [23.1%]), followed by nonfa-
tal MI (240 [14.4%]), CV death (172 [10.3%]), nonfatal stroke
81 [4.9%]), and hospitalization for unstable angina pectoris (81
[4.9%]). This was different compared with the distribution of
first expanded MACE (n = 2010 events) of which nonfatal MI
(495 [24.6%]) was the most prevalent, followed by coronary
revascularization (352 [17.5%]), hospitalization for heart fail-
ure (346 [17.2%]), and CV death (325 [16.2%]) (eFigure in the
Supplement).
Risk of Total MACE, Total Expanded MACE,
and Individual CV End Points
The unadjusted AG model with a robust variance estimation
showed that liraglutide was associated with a 15.7% relative
risk reduction for total MACE vs placebo (HR, 0.84; 95% CI,
0.76-0.93). In the adjusted AG (HR, 0.86; 95% CI, 0.78-0.95)
and PWP model (HR, 0.87; 95% CI, 0.78-0.95), risk estimates
were slightly higher. In addition, liraglutide was associated
with a 13.4% relative risk reduction for total expanded MACE
vs placebo (unadjusted AG model: HR, 0.87; 95% CI, 0.81-
0.93), and when all individual CV end points were consid-
ered (with the exception of unstable angina pectoris), lira-
glutide was associated with lower risk vs placebo (eTable in
the Supplement).
Figure 2. Mean Total Major Adverse Cardiovascular Events





























Mean cumulative function estimated using the Nelson-Aalen nonparametric
method. The number needed to treat to avoid 1 event was based on the mean
cumulative function at 3 years without accounting for competing risk. Dashed
lines indicate liraglutide or placebo with competing risk. The P value was
calculated for no treatment difference in the mean cumulative function
with competing risk. The 3-point composite end point included time to
cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke
(number needed to treat at 3 years: 43 patients). The 6-point composite end
points included the 3-point MACE end points plus coronary revascularization
and hospitalization for heart failure or unstable angina pectoris (number
needed to treat at 3 years: 23 patients).






















Age, mean (SD), y 64.0 (7.2) 64.1 (7.0) 64.1 (7.1) 65.5 (7.7) 65.8 (8.2) 65.6 (8.0) 65.0 (7.4) 66.2 (8.3) 65.7 (7.9)
Male, No. (%) 2586 (63.7) 2507 (63.0) 5093 (63.4) 361 (70.6) 402 (70.8) 763 (70.7) 64 (66.0) 83 (65.9) 147 (65.9)
Diabetes duration,
mean (SD), y
12.7 (7.9) 12.7 (8.0) 12.7 (7.9) 13.3 (8.1) 13.4 (8.5) 13.4 (8.3) 15.1 (8.7) 13.8 (8.7) 14.4 (8.7)
Hemoglobin A1c,
mean (SD), %








541 (13.3) 533 (13.4) 1074 (13.4) 94 (18.4) 99 (17.4) 193 (17.9) 18 (18.6) 20 (15.9) 38 (17.0)
Body weight,
mean (SD), kg
91.7 (21.1) 91.4 (20.7) 91.6 (20.9) 93.1 (22.0) 92.6 (21.5) 92.8 (21.7) 93.0 (20.1) 92.2 (20.6) 92.6 (20.3)
Body mass index,
mean (SD)b
32.6 (6.3) 32.5 (6.3) 32.5 (6.3) 32.3 (6.4) 32.4 (6.4) 32.4 (6.4) 32.9 (6.5) 32.8 (6.2) 32.8 (6.3)
Abbreviations: LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of
Cardiovascular Outcome Results; MACE, major adverse cardiovascular events
(3-point composite end point of time to cardiovascular death, nonfatal
myocardial infarction, or nonfatal stroke).
a New York Heart Association class II or III.
b Calculated as weight in kilograms divided by height in meters squared.
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The post hoc inclusion of recurrent events increased the
power for showing superiority for time to events adjudica-
tion committee–confirmed MACE from 72.2% (primary end
point of first MACE, Cox proportional hazards regression
model) to 82.4% (post hoc end point of recurrent MACE, PWP
model using log-HR with corresponding SEs).
Discussion
We hypothesized that liraglutide, in addition to reducing first
MACE in patients with type 2 diabetes and high risk of CV
events, would also be associated with a reduction in recur-
rent CV events and therefore total events compared with pla-
cebo. It has been previously reported2 that, in LEADER, lira-
glutide was associated with a reduced relative risk of first MACE
by 13% compared with placebo. In this post hoc analysis, the
relative risk reduction for total MACE was 15.7%. For total
MACE, this translated into 43 patients needing treatment with
liraglutide to prevent 1 event within 3 years, which was nota-
bly lower compared with the NNT of 66 calculated based on
first MACE alone.2 Similarly, for expanded total MACE, the NNT
was 23 vs 49 for expanded first MACE. To our knowledge, these
are the first such data relating to liraglutide and may help guide
clinical decisions because the use of liraglutide was associ-
ated with reduced first and recurrent MACE among patients
at risk for CV disease.
Although it is common in CV outcomes trials to censor pri-
mary outcome data after the first event has occurred,1,2,5-7
many individuals have additional CV events that are cap-
tured and adjudicated but not used in primary statistical ef-
ficacy analyses. The clinical and scientific utility of capturing
the total events may increase the power of the study, assum-
ing that efficacy is maintained against recurrent events and pa-
tients adhere to treatment. It may also allow for a more mean-
ingful assessment of absolute risk reduction and NNT with
the pharmacotherapy. This concept is gaining support in other
CV risk-reduction trials, including those of lipid-lowering16
and antiplatelet therapy,17 as well as cost-effectiveness
assessments.18,19
As with most clinical trials, study treatment (liraglutide or
placebo) began at the start of the LEADER trial. However, with
the cardioprotective benefit of liraglutide evident in first MACE
and total MACE, the question arises as to how the timing and
duration of liraglutide treatment before and after a CV event
is associated with future CV events. This is a question of
clinical importance that has yet to be tested in a randomized
clinical trial.
Recurrent event analyses have been conducted for differ-
ent treatments and diseases.16,17,20 These trials investigated pa-
tients with different underlying conditions16,17,20 than those
in the LEADER trial,2 making direct comparisons between the
size of treatment effects on recurrent events difficult. Al-
though the proportion of recurrent events reported in the
LEADER trial was within the range of those reported in other
trials (18%-37%),16,17,20 the benefit associated with liraglu-
tide treatment for risk of first and recurrent events was a 15.7%
reduction. Although this reduction was an improvement from
the 13% lower risk with liraglutide observed when primary
events only were analyzed,2 it may seem modest compared
with other trials. For example, in an analysis of ischemic events
(CV death, nonfatal MI, nonfatal stroke, coronary revascular-
ization, or hospitalization for unstable angina) among pa-
tients with established CV disease or type 1 or type 2 diabetes
who were treated with statins, icosapent ethyl (an antilipid
therapy) reduced the relative risk of total events by 30% com-
pared with placebo during 4.9 years.20 Although effect sizes
for recurrent events will inevitably vary between treatments
and in different patient populations, these previously pub-
lished data16,20 suggest that recurrent events occur in a sub-
stantial proportion of patients and should be considered when
making clinical decisions. Coronary revascularization was the
most prevalent recurrent (expanded MACE) event in the
LEADER trial, highlighting the importance of such events
within the context of population health. Effectively treating
patients to reduce recurrent events could reduce time spent
in the hospital, and it is for such reasons that recurrent events
have been included in some recent cost-effectiveness
studies.18,19
Limitations
This analysis has limitations. Analyses of recurrent events
may overestimate the contribution of patients experiencing
MACE early in a trial,8 cannot differentiate between cardio-
protective mechanisms of a drug that may differ between
first and subsequent events16 and do not account for the
decreasing compliance that is nominally reported as CV out-
comes trials progress.16 Although the mean percentage of
time that patients received trial treatment was 84% in the
liraglutide group and 83% in the placebo group,2 adherence
to study drug during the period between first and recurrent
MACE was uncertain. This lack of data is a potential limita-
tion; however, it should be balanced by the 96.8% of
patients who completed a final study visit, died, or had a pri-
mary outcome2 showing the overall robustness of the data.
There was also a lack of data about CV medication use
between first and recurrent MACE, which potentially biased
the results. Also, although inclusion of recurrent events
increased the post hoc power, the LEADER trial was not
designed to test for treatment differences in recurrent
events. Although such analyses of recurrent events may
amplify any positive result for primary events (because
counting each recurrent event individually may augment the
effect size), in CV outcomes trials, this has to be considered
in parallel with any differences in CV vs non-CV death. For
example, in these analyses of recurrent events for the com-
posite end point MACE and expanded MACE, non-CV death
was a competing event. Because only a marginal nonsignifi-
cant treatment difference was observed for non-CV death in
the LEADER trial (HR, 0.95; 95% CI, 0.76-1.18),2 it was likely
that this competing risk would only have a marginal effect
on the results. This was supported by the sensitivity analy-
ses of the mean cumulative function for both end points. For
the analyses of the individual components, CV death and
non-CV death were competing events. A treatment effect in
favor of liraglutide was observed for all-cause death in the
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LEADER trial with an HR of 0.85 (95% CI, 0.74-0.92).2 Thus,
the results for the recurrent models applied for the indi-
vidual components in expanded MACE could potentially be
biased toward neutrality of the treatment effects.
Another potential limitation was related to the statistical ap-
proaches used. In a randomized clinical trial setting, the PWP
model has been criticized because its use of the event history
may reduce the estimated treatment effect,10 and, further-
more, there could be a selection bias because randomization is
not preserved after the first event. However, in a recent study
by Ozga and colleagues,11 the PWP model seemed to be advan-
tageous (followed by the AG model) in estimating treatment ef-
fects. It met most data scenarios for clinical trials with compos-
ite end points including fatal events compared with marginal
recurrent models such as the Wei-Lin-Weissfeld model.11
Conclusions
These results suggest that liraglutide treatment is associated
with a reduction in risk of total (first and recurrent) MACE com-
pared with placebo among patients with type 2 diabetes and
high risk of cardiovascular events. This analysis supports the
findings of an absolute benefit of liraglutide treatment with
respect to the overall burden of CV events in this high-risk
patient population.
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